I Study Of Its Investigational Ros1 Inhibitor, Taletrectinib

Nuvation Bio

01/06/2024 13:29

June 1 (Reuters) - Nuvation Bio Inc  NUVB.N :
    * NUVATION BIO ANNOUNCES DATA FROM PIVOTAL PHASE 2 TRUST-I
STUDY
OF ITS INVESTIGATIONAL ROS1 INHIBITOR, TALETRECTINIB, ARE
PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY AND REPORTED AT
2024 ASCO ANNUAL MEETING
    * TUMORS SHRANK IN 91% OF TALETRECTINIB-TREATED PATIENTS
WITH
ADVANCED ROS1-POSITIVE NSCLC WHO WERE ROS1 TKI-NAÏVE
    * RESPONSES WERE DURABLE WITH LONG-TERM FOLLOW-UP; 71% OF
TKI-NAÏVE PATIENTS WERE STILL PROGRESSION-FREE AT TWO YEARS
    * NUVATION BIO: LOOK FORWARD TO FURTHER ADVANCING
TALETRECTINIB
AND PLAN TO SHARE RESULTS FROM GLOBAL, PIVOTAL TRUST-II STUDY BY
END OF 2024
    * AIM TO BECOME A COMMERCIAL-STAGE ORGANIZATION BY END OF
2025

Source text for Eikon:  ID:nBwcdKYxJa 
Further company coverage:  NUVB.N 

 ((reuters.briefs@thomsonreuters.com;))